INDP on Nasdaq

Indaptus Therapeutics, Inc.

American pharmaceutical preparations company based in New York.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with another stock.

TickerINDP on Nasdaq
IndustryPharmaceutical Preparations
HeadquartersDE
Incorporated inDE²
Business address3 Columbus Circle, 15Th Floor, New York, Ny 10019²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income³⁴⁵⁶⁷-$19.8M in 2025+451% since 2020

Net income³⁴⁵⁶⁷-$20.8M in 2025+482% since 2020

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁷

Period ending	2025-12-31	2024-12-31
Research and development	$9.3M	$7.3M
General and administrative	$10.5M	$8.1M
Total operating expenses	$19.8M	$15.4M
Loss from operations	-$19.8M	-$15.4M
Other income, net	$138.0K	$343.7K
Change in fair value of convertible promissory notes	-$1.2M
Net loss	-$20.8M	-$15.0M
Net loss available to common stockholders per share of common stock, basic	-$21.58	-$44.96
Net loss available to common stockholders per share of common stock, diluted	-$21.58	-$44.96
Weighted average number of shares used in calculating net loss per share, basic	966.1K shares	334.1K shares
Weighted average number of shares used in calculating net loss per share, diluted	966.1K shares	334.1K shares

Total assets³⁴⁵⁶⁷$9.3M in 2025+424% since 2020

Total liabilities³⁴⁵⁶$3.4M in 2024+68% since 2020

Shareholders’ equity³⁴⁵⁶⁷$3.2M in 2025−2% since 2019

Cash³⁴⁵⁶⁷$8.5M in 2025+420% since 2020

Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.⁷

Period ending	2025-12-31	2025-06-30	2024-12-31	2023-12-31
Cash and cash equivalents	$8.5M		$5.8M
Prepaid expenses and other current assets	$802.5K		$831.6K
Total current assets	$9.3M		$6.6M
Right-of-use asset			$82.2K
Other assets - deposits to third parties			$638.3K
Total non-current assets			$720.4K
Total assets	$9.3M		$7.3M
Accounts payable and other current liabilities	$6.2M		$3.3M
Operating lease liability, current portion			$84.2K
Total current liabilities	$6.2M		$3.4M
Common stock: $0.01 par value, 200,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 2,167,324 shares issued and outstanding as of December 31, 2025 and 428,799 shares issued and outstanding as of December 31, 2024	$21.7K		$4.3K
Preferred stock: $0.01 par value, 5,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 1,000,000 shares issued and outstanding as of December 31, 2025 and no shares issued and outstanding as of December 31, 2024	$10.0K
Additional paid in capital	$84.4M		$64.4M
Accumulated deficit	-$81.3M		-$60.4M
Total stockholders equity	$3.2M		$3.9M	$12.1M
Total liabilities and stockholders equity	$9.3M		$7.3M
Common stock, par value	$0.01		$0.01
Common stock, shares authorized	200.0M shares		200.0M shares
Common stock, shares issued	2.2M shares		428.8K shares
Common stock, shares outstanding	2.2M shares	605.0K shares	428.8K shares
Preferred stock, par value	$0.01		$0.01
Preferred stock, shares authorized	5.0M shares		5.0M shares
Preferred stock, shares issued	1.0M shares		0 shares
Preferred stock, shares outstanding	1.0M shares		0 shares

Period ending	2025-12-31	2025-06-30	2024-12-31	2023-12-31
Cash and cash equivalents	$8.5M		$5.8M
Prepaid expenses and other current assets	$802.5K		$831.6K
Total current assets	$9.3M		$6.6M
Right-of-use asset			$82.2K
Other assets - deposits to third parties			$638.3K
Total non-current assets			$720.4K
Total assets	$9.3M		$7.3M
Accounts payable and other current liabilities	$6.2M		$3.3M
Operating lease liability, current portion			$84.2K
Total current liabilities	$6.2M		$3.4M
Common stock: $0.01 par value, 200,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 2,167,324 shares issued and outstanding as of December 31, 2025 and 428,799 shares issued and outstanding as of December 31, 2024	$21.7K		$4.3K
Preferred stock: $0.01 par value, 5,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 1,000,000 shares issued and outstanding as of December 31, 2025 and no shares issued and outstanding as of December 31, 2024	$10.0K
Additional paid in capital	$84.4M		$64.4M
Accumulated deficit	-$81.3M		-$60.4M
Total stockholders equity	$3.2M		$3.9M	$12.1M
Total liabilities and stockholders equity	$9.3M		$7.3M
Common stock, par value	$0.01		$0.01
Common stock, shares authorized	200.0M shares		200.0M shares
Common stock, shares issued	2.2M shares		428.8K shares
Common stock, shares outstanding	2.2M shares	605.0K shares	428.8K shares
Preferred stock, par value	$0.01		$0.01
Preferred stock, shares authorized	5.0M shares		5.0M shares
Preferred stock, shares issued	1.0M shares		0 shares
Preferred stock, shares outstanding	1.0M shares		0 shares

Cash from operations³⁴⁵⁶⁷-$14.8M in 2025+346% since 2020

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁷

Period ending	2025-12-31	2024-12-31
Net loss	-$20.8M	-$15.0M
Depreciation		$735
Stock-based compensation	$1.4M	$2.3M
Change in fair value of convertible promissory notes	$1.2M
Prepaid expenses and other current and non- current assets	$667.3K	-$81.9K
Accounts payable and other current liabilities	$2.8M	$474.1K
Operating lease right-of-use asset and liability, net	-$2.0K	$142
Net cash used in operating activities	-$14.8M	-$12.3M
Proceeds from issuance of convertible promissory notes	$5.7M
Proceeds from issuance of shares of common stock and warrants	$6.4M	$5.5M
Proceeds from issuance of preferred stock	$6.0M
Proceeds from exercise of pre-funded warrants	$1.9K
Issuance costs	-$569.5K	-$762.7K
Net cash provided by financing activities	$17.5M	$4.7M
Net increase (decrease) in cash and cash equivalents	$2.7M	-$7.6M
Transaction costs in accounts payable and other current liabilities		$163.3K
Settlement of convertible promissory notes	$6.9M
Issuance of commitment shares	$109

Compare Indaptus Therapeutics, Inc. with another company

Leadership

Who has led Indaptus Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chief financial officer

Nir Sassi2021–now

Chief operating officer

Walt Addison Linscott2024–now

2025

Chief executive officerJunyi Dai Apr 2, 2026 to now¹⁰
Chief executive officerDavid E. Lazar Dec 23, 2025 to Apr 2, 2026¹¹
Chief executive officerJeffrey A. Meckler Aug 2, 2021 to Dec 23, 2025¹²
Chief financial officerNir Sassi Aug 2, 2021 to now¹³
Chief operating officerWalt Addison Linscott Jan 23, 2024 to now¹⁴

Board members and other officers (19)

Chief Medical OfficerRoger J. Waltzman Aug 7, 2023 to Oct 10, 2024¹⁵
Chief Medical OfficerBoyan Vesselinov Litchev Feb 2, 2022 to Dec 19, 2022¹⁶
Chief Business OfficerWalt Addison Linscott Aug 2, 2021 to Jan 20, 2023¹⁷
CSO and DirectorMichael James Newman Aug 6, 2021 to now¹⁸
Board memberDavid Natan Jan 12, 2026 to now¹⁹
Board memberMatthew Charles McMurdo Feb 26, 2026 to now²⁰
Board memberJerome D. Jabbour Feb 27, 2026 to now²¹
Board memberDavid E. Lazar Mar 24, 2026 to now²²
Board memberAvraham Ben-Tzvi Dec 23, 2025 to now²³
Board memberRobert Martell Feb 14, 2023 to now²⁴
Board memberAnthony J. Maddaluna Aug 2, 2021 to now²⁵
Board memberHila Karah Aug 2, 2021 to now²⁶
Board memberJeffrey A. Meckler Aug 2, 2021 to now¹²
Board memberRoger Pomerantz Aug 2, 2021 to now²⁷
Board memberWilliam B. Hayes Aug 2, 2021 to now²⁸
Board memberBrian O'Callaghan Aug 6, 2021 to Oct 3, 2022²⁹
Board memberHoonmo Lee Aug 6, 2021 to Aug 6, 2021³⁰
Board memberMichael James Newman Aug 6, 2021 to now¹⁸
Board memberMark John Gilbert Dec 8, 2021 to now³¹

Former names

Intec Parent Inc.Apr 20, 2021 to Aug 3, 2021²

Timeline

Apr 2, 2026New chief executive Junyi Dai becomes CEO¹⁰
Dec 23, 2025New chief executive David E. Lazar becomes CEO¹¹
Aug 2, 2021New chief executive Jeffrey A. Meckler becomes CEO¹²

Filings

281 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 68 major events, 87 insider forms, 21 large holders, 5 private raises, 80 other. The latest 20:

The 281 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 21 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

Jun 12, 2025Raised $2.3 million in a private offering of securities Form D: $5 million offered in all Form D
Jan 16, 2025Raised $2.2 million in a private offering of equity Form D: 16 investors so far Form D
Nov 22, 2024Raised $227,127 in a private offering of securities Form D: 20 investors so far Form D
Aug 7, 2024Raised $205,480 in a private offering of securities Form D: 12 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Geode Capital Management, LLC	56,470	$169.4K	0.0%	+29,463
Jane Street Group, LLC	53,811	$161.4K	0.0%	New
Vanguard Capital Management LLC	33,652	$101.0K	0.0%	New
Vanguard Fiduciary Trust Co	13,967	$41.9K	0.0%	New
Millennium Management LLC	11,586	$34.8K	0.0%	New
Morgan Stanley	8,936	$26.8K	0.0%	+6,239
UBS Group AG	478	$1.4K	0.0%	New
Hrt Financial LP	206,077	$618	0.0%	New
SBI Securities Co., Ltd.	17	$51	0.0%	No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARIndaptus Therapeutics, Inc. filings on SEC EDGAR
2
SEC EDGARIndaptus Therapeutics, Inc. filings on SEC EDGAR
3
SEC EDGARIndaptus Therapeutics, Inc. 10-K for fiscal 2020
4
SEC EDGARIndaptus Therapeutics, Inc. 10-K for fiscal 2021
5
SEC EDGARIndaptus Therapeutics, Inc. 10-K for fiscal 2022
6
SEC EDGARIndaptus Therapeutics, Inc. 10-K for fiscal 2023
7
SEC EDGARIndaptus Therapeutics, Inc. 10-K for fiscal 2024
8
SEC EDGARIndaptus Therapeutics, Inc. 10-Q for fiscal 2026
9
SEC EDGARIndaptus Therapeutics, Inc. 10-Q for fiscal 2026
10
SEC EDGARJunyi Dai, Chief executive officer
11
SEC EDGARDavid E. Lazar, Chief executive officer
12
SEC EDGARJeffrey A. Meckler, Chief executive officer
13
SEC EDGARNir Sassi, Chief financial officer
14
SEC EDGARWalt Addison Linscott, Chief operating officer
15
SEC EDGARRoger J. Waltzman, Chief Medical Officer
16
SEC EDGARBoyan Vesselinov Litchev, Chief Medical Officer
17
SEC EDGARWalt Addison Linscott, Chief Business Officer
18
SEC EDGARMichael James Newman, CSO and Director
19
SEC EDGARDavid Natan, Board member
20
SEC EDGARMatthew Charles McMurdo, Board member
21
SEC EDGARJerome D. Jabbour, Board member
22
SEC EDGARDavid E. Lazar, Board member
23
SEC EDGARAvraham Ben-Tzvi, Board member
24
SEC EDGARRobert Martell, Board member
25
SEC EDGARAnthony J. Maddaluna, Board member
26
SEC EDGARHila Karah, Board member
27
SEC EDGARRoger Pomerantz, Board member
28
SEC EDGARWilliam B. Hayes, Board member
29
SEC EDGARBrian O'Callaghan, Board member
30
SEC EDGARHoonmo Lee, Board member
31
SEC EDGARMark John Gilbert, Board member